Sign in
8-K

Current Report

Viridian Therapeutics, Inc.\DE Filed Acc 0001590750-19-000040

Agreement ended · Results of operations · Exit or restructuring costs

  • Item 1.02 Termination of a material definitive agreement
  • Item 2.02 Results of operations and financial condition
  • Item 2.05 Costs associated with exit or disposal activities

From the SEC's structured data for this filing

Loading mgen-q220198k.htm…